查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1638738

复杂区域疼痛症候群 (CRPS) 市场机会、成长驱动因素、产业趋势分析与预测 2024 - 2032 年

Complex Regional Pain Syndrome (CRPS) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球复杂区域疼痛症候群 (CRPS) 市场价值为 1.09 亿美元，预计 2024 年至 2032 年复合年增长率为 2.4%。疼痛状况，以及对个人化治疗方法的日益关注。

製药和生物技术公司正在积极开发 CRPS 特异性疗法，旨在减少症状的持续时间和严重程度。尖端的诊断技术可以更早、更准确地识别 CRPS，从而加快干预措施并改善结果。非侵入性诊断影像和标靶药物治疗变得越来越普遍，从而可以采用个人化方法来解决每位患者独特的病情和疼痛状况。

CRPS 市场按疾病类型分为 CRPS I、CRPS II 和 CRPS-NOS，其中 CRPS I（也称为反射性交感神经营养不良）在 2023 年占据 9120 万美元的重要份额。 CRPS I 发生在受伤或患病后，但受影响区域没有直接神经损伤。诊断意识的不断提高和进步正在刺激对有效治疗的需求，进一步推动市场成长。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 1.09 亿美元
预测值 1.342 亿美元
复合年增长率 2.4%

从治疗类型来看，市场分为药物和治疗，到2023年，药物细分市场将占据66.1%的可观份额。常用药物包括非类固醇抗发炎药、皮质类固醇、抗惊厥药和双磷酸盐。此外，药物治疗的进步，包括新的药物类别和神经阻断技术，正在扩大选择并推动改善患者的治疗结果。

美国复杂区域疼痛症候群市场预计将以2.3% 的复合年增长率成长，到2032 年将达到4,980 万美元。增加的手术和意外发生率受伤。此外，对研究的大量投资正在促进疼痛管理的创新，特别是透过神经刺激和针对性治疗。美国政府的措施也透过促进改善疼痛管理实践和减少阿片类药物依赖的努力来支持市场扩张，从而推进该地区的 CRPS 治疗方案。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • CRPS 盛行率增加
      • 疼痛管理疗法的进展
      • 意识和诊断率不断提高
    • 产业陷阱与挑战
      • 治疗费用高
      • 现有疗法的潜在副作用
  • 成长潜力分析
  • 监管环境
  • 未来市场趋势
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：依疾病类型，2021-2032 年

  • 主要趋势
  • CRPS一期
  • CRPS II
  • CRPS一NOS

第 6 章：市场估计与预测：依处理方式，2021-2032 年

  • 主要趋势
  • 药物
    • 止痛药
    • 抗忧郁药
    • 皮质类固醇
    • 阿片类药物
    • 其他药物
  • 治疗
    • 物理治疗
    • 鞘内药物泵
    • 脊髓刺激
    • 手术交感神经切除手术
    • 其他疗法

第 7 章：市场估计与预测：按管理途径，2021-2032 年

  • 主要趋势
  • 口服
  • 可注射
  • 其他给药途径

第 8 章：市场估计与预测：依最终用途，2021-2032 年

  • 主要趋势
  • 医院
  • 诊所
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021-2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Abbott Laboratories
  • AbbVie
  • Averitas Pharma
  • Boston Scientific
  • Collegium Pharmaceutical
  • Eli Lilly and Company
  • Mallinckrodt Pharmaceuticals
  • Medtronic
  • Nevro
  • Pfizer
  • Sandoz
  • Teva Pharmaceutical
简介目录
Product Code: 12148

The Global Complex Regional Pain Syndrome (CRPS) Market was valued at USD 109 million in 2023 and is projected to grow at a CAGR of 2.4% from 2024 to 2032. Growth in this market is largely driven by the advancements in diagnostic technologies, rising prevalence of chronic pain conditions, and an increasing focus on personalized treatment approaches.

Pharmaceutical and biotechnology companies are actively developing CRPS-specific therapies aimed at reducing the duration and severity of symptoms. Cutting-edge diagnostic technologies enable earlier and more accurate identification of CRPS, leading to faster interventions and improved outcomes. Non-invasive diagnostic imaging and targeted pharmacological treatments are becoming more prevalent, allowing for a personalized approach that addresses each patient's unique condition and pain profile.

The CRPS market is segmented by disease type into CRPS I, CRPS II, and CRPS-NOS, with CRPS I, also known as Reflex Sympathetic Dystrophy, accounting for a significant share of USD 91.2 million in 2023. Representing approximately 90% of CRPS cases, CRPS I occurs following an injury or illness without direct nerve damage to the affected area. Growing awareness and advancements in diagnostics are spurring demand for effective treatments, further propelling market growth.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$109 Million
Forecast Value$134.2 Million
CAGR2.4%

In terms of treatment type, the market is divided into medication and therapy, with the medication segment holding a substantial share of 66.1% in 2023. Medications are essential for pain relief and symptom management, improving the quality of life for CRPS patients. Commonly used drugs include NSAIDs, corticosteroids, anticonvulsants, and bisphosphonates. Additionally, advancements in pharmacological treatments, including new drug classes and nerve block techniques, are expanding options and driving improved patient outcomes.

The U.S. complex regional pain syndrome market is expected to grow at a CAGR of 2.3%, reaching USD 49.8 million by 2032. Factors contributing to this growth include a high prevalence of chronic pain conditions, robust healthcare infrastructure, and increasing rates of surgeries and accidental injuries. Furthermore, substantial investment in research is fostering innovation in pain management, particularly through neurostimulation and targeted treatments. Government initiatives in the U.S. also support market expansion by promoting improved pain management practices and efforts to reduce opioid dependence, advancing CRPS treatment options in the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of CRPS
      • 3.2.1.2 Advancements in pain management therapies
      • 3.2.1.3 Rising awareness and diagnosis rates
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Potential side effects of available therapies
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Pipeline analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Disease Type, 2021-2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 CRPS I
  • 5.3 CRPS II
  • 5.4 CRPS-NOS

Chapter 6 Market Estimates & Forecast, By Treatment, 2021-2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Medication
    • 6.2.1 Analgesics
    • 6.2.2 Antidepressants
    • 6.2.3 Corticosteroids
    • 6.2.4 Opioids
    • 6.2.5 Other medications
  • 6.3 Therapy
    • 6.3.1 Physical therapy
    • 6.3.2 Intrathecal drug pump
    • 6.3.3 Spinal cord stimulation
    • 6.3.4 Surgical sympathectomy
    • 6.3.5 Other therapies

Chapter 7 Market Estimates & Forecast, By Route of Administration, 2021-2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Other routes of administration

Chapter 8 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Other end users

Chapter 9 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 MEA
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 AbbVie
  • 10.3 Averitas Pharma
  • 10.4 Boston Scientific
  • 10.5 Collegium Pharmaceutical
  • 10.6 Eli Lilly and Company
  • 10.7 Mallinckrodt Pharmaceuticals
  • 10.8 Medtronic
  • 10.9 Nevro
  • 10.10 Pfizer
  • 10.11 Sandoz
  • 10.12 Teva Pharmaceutical